Interacciones de Disulfiram

WARNING Disulfiram should never be administered to a patient when he is in a state of alcohol intoxication, or without his full knowledge. (etiqueta de Disulfiram, Advertencia en recuadro)

Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (etiqueta de Bosentán, Interacciones medicamentosas)

Avoid using NUMBRINO in patients taking disulfiram. (etiqueta de Cocaína, Interacciones medicamentosas)

…reactions to dronabinol include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, throat tightness [see Adverse Reactions ( 6.2 )] . with a history of a hypersensitivity reaction to alcohol. who are receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days [see Warning and Precautions ( 5.3 )] . (etiqueta de Dronabinol, Contraindicaciones)

Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (etiqueta de Macitentán, Interacciones medicamentosas)

CONTRAINDICATIONS Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. (etiqueta de Disulfiram, Contraindicaciones)

CONTRAINDICATIONS Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. (etiqueta de Disulfiram, Contraindicaciones)

Alcohols, Disulfiram: Alcoholic beverages and preparations containing ethanol or propylene glycol should be avoided during tinidazole therapy and for 3 days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur. (etiqueta de Tinidazol, Interacciones medicamentosas)

Disulfiram Decreases theophylline clearance by inhibiting hydroxylation and demethylation. (etiqueta de Aminofilina, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (etiqueta de Avanafilo, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (etiqueta de Carvedilol, Interacciones medicamentosas)

Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g., fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of celecoxib. (etiqueta de Celecoxib, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co- administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. (etiqueta de Diclofenaco, Interacciones medicamentosas)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g., voriconazole) may enhance the exposure and toxicity of diclofenac [see Clinical Pharmacology (12.3) ] whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of diclofenac. (etiqueta de Diclofenaco y misoprostol, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (etiqueta de Elexacaftor, tezacaftor e ivacaftor, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS RECEIVING PHENYTOIN AND ITS CONGENERS, SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION. (etiqueta de Disulfiram, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

…(cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels… (etiqueta de Fosfenitoína, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (etiqueta de Lacosamida, Interacciones medicamentosas)

Thus concomitant usage of CYP2C9 inhibitors (such as amiodarone, fluconazole, and sulphaphenazole) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance [ see Use in Specific Populations ( 8.8 ); and Clinical Pharmacology ( 12.3 , 12.5 ) ]. (etiqueta de Meloxicam, Interacciones medicamentosas)

…salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g., amiodarone, fluconazole, voriconazole, sulfinpyrazone) or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol. (etiqueta de Nateglinida, Interacciones medicamentosas)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (etiqueta de Ramelteón, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (etiqueta de Rosuvastatina, Interacciones medicamentosas)

Disulfiram Decreases theophylline clearance by inhibiting hydroxylation and demethylation. (etiqueta de Teofilina, Interacciones medicamentosas)

CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. (etiqueta de Torasemida, Interacciones medicamentosas)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (etiqueta de Disulfiram, Interacciones medicamentosas)

Zafirlukast exposure is likely to be increased by other moderate and strong CYP2C9 inhibitors. (etiqueta de Zafirlukast, Precauciones)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (etiqueta de Amitriptilina, Interacciones medicamentosas)

Additionally, no disulfiram-like reactions were reported in a study conducted in 22 healthy volunteers administered cefotaxime and ethanol. (etiqueta de Cefotaxima, Interacciones medicamentosas)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (etiqueta de Clopidogrel, Interacciones medicamentosas)

Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status, the disulfiram should be discontinued if such signs appear. (etiqueta de Disulfiram, Interacciones medicamentosas)

Alcohol: Exceptional cases have been reported of a disulfiram-like reaction to alcohol, characterized by flushing, rash, peripheral edema, nausea and headache. (etiqueta de Ketoconazol, Interacciones medicamentosas)

Disulfiram/metronidazole KALETRA oral solution contains ethanol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole). (etiqueta de Lopinavir y ritonavir, Interacciones medicamentosas)

Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). (etiqueta de Omeprazol, Interacciones medicamentosas)

Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). (etiqueta de Omeprazol y bicarbonato de sodio, Interacciones medicamentosas)

Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. (etiqueta de Terbinafina, Interacciones medicamentosas)

Toremifene is a weak inhibitor of CYP2C9. (etiqueta de Toremifeno, Interacciones medicamentosas)

The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a HIV protease inhibitor and a highly strong CYP3A4 inhibitor, which also inhibits CYP2C9. (etiqueta de Vardenafilo, Interacciones medicamentosas)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (etiqueta de Venlafaxina, Interacciones medicamentosas)

The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (etiqueta de Acamprosato, Interacciones medicamentosas)